EMAIL THIS PAGE TO A FRIEND

Molecular pharmaceutics

Targeted decationized polyplexes for siRNA delivery.


PMID 25384057

Abstract

The applicability of small interfering RNA (siRNA) in future therapies depends on the availability of safe and efficient carrier systems. Ideally, siRNA delivery requires a system that is stable in the circulation but upon specific uptake into target cells can rapidly release its cargo into the cytoplasm. Previously, we evaluated a novel generation of carrier systems ("decationized" polyplexes) for DNA delivery, and it was shown that folate targeted decationized polyplexes had an excellent safety profile and showed intracellular triggered release upon cell specific uptake. Targeted decationized polyplexes consist of a core of disulfide cross-linked poly(hydroxypropyl methacrylamide) (pHPMA) stably entrapping nucleic acids and a shell of poly(ethylene glycol) (PEG) decorated with folate molecules. In the present study, the applicability of folate targeted decationized polyplexes for siRNA delivery was investigated. This required optimization of the carrier system particularly regarding the cross-linking density of the core of the polyplexes. Stable and nanosized siRNA decationized polyplexes were successfully prepared by optimizing the cross-link density of their core. Upon incubation in human plasma, a significant portion of siRNA remained entrapped in the decationized polyplexes as determined by fluorescence correlation spectroscopy (FCS). When tested in a folate receptor overexpressing cell line stably expressing luciferase, Skov3-luc, sequence specific gene silencing was observed. As expected, neither interference on the intrinsic luciferase expression nor on the cell metabolic activity (determined by XTT) was induced by the free-polymer or the siRNA polyplexes. In conclusion, targeted decationized polyplexes are safe and stable carriers that interact with the targeted cells and rapidly disassemble upon cell entry making them promising siRNA delivery systems.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

156914
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
453323
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
424005
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D
C2D6OS
417939
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
417920
Dimethyl sulfoxide-d6, "100%", 99.96 atom % D, contains 1 % (v/v) TMS
C2D6OS
570672
Dimethyl sulfoxide-d6, anhydrous, 99.9 atom % D
C2D6OS
569585
Dimethyl sulfoxide-d6, 99.9 atom % D, anhydrous
C2D6OS
151874
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
522058
Dimethyl sulfoxide-d6, 99.9 atom % D
C2D6OS
612324
Dimethyl sulfoxide-d6, "Special HOH", ≥99.9 atom % D
C2D6OS
716731
Dimethyl sulfoxide-d6, "Special HOH", ≥99.9 atom % D
C2D6OS
296147
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
574341
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 0.03 % (v/v) TMS
C2D6OS
185965
Dimethyl sulfoxide-d6, 99.9 atom % D, contains 1 % (v/v) TMS
C2D6OS
175943
Dimethyl sulfoxide-d6, 99.5 atom % D
C2D6OS
437697
Dimethyl sulfoxide-d6, 99.5 atom % D, contains 0.1 % (v/v) TMS
C2D6OS
724335
Dimethyl sulfoxide-d6, contains 0.07 wt. % TSP-d4, 99.9 atom % D, 99% (CP)
C2D6OS
85886
Streptomycin solution, ~1 mg/mL in 1 mM EDTA, analytical standard
C21H39N7O12 · 1.5H2SO4
S1400000
Streptomycin sulfate, European Pharmacopoeia (EP) Reference Standard
C21H39N7O12 · 1.5H2O4S
S6501
Streptomycin sulfate salt, powder
C21H39N7O12 · 1.5H2O4S
S9137
Streptomycin sulfate salt, powder, BioReagent, suitable for cell culture
C21H39N7O12 · 1.5H2O4S
S1277
Streptomycin sulfate salt, powder, BioXtra, suitable for mouse embryo cell culture
C21H39N7O12 · 1.5H2O4S